NCT04651179已完成不适用
A Retrospective Observational Study of the Effectiveness of Gemcitabine -Docetaxel in Patients With Relapsed Osteosarcoma Who Have Been Treated With HD-IFO in First Line Treatment
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna8 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2020年4月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 8
- 主要终点
- Response to Gemcitabina - Docetaxel Treatment
研究概览
简要总结
A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 4 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at diagnosis of high grade osteosarcoma >= 4
- •Received first line treatment with HD IFO
- •Following HD IFO treatment, they have been diagnosed refractory disease and they satisfy at least one of the following criteria :
- •Relapsed in the first 24 month following the initial diagnosis, regardless of location and resectability
- •Lung relapsed disease with more than 2 nodules diagnosed over 24 months from the initial diagnosis
- •Non resectable relapsed disease diagnosed over 24 months from the initial diagnosis Before or during GEMDOX treatment, eligible patients may have been subject to metastasectomy
排除标准
- 未提供
结局指标
主要结局
Response to Gemcitabina - Docetaxel Treatment
时间窗: 12 months
assessed as overall survival (12 months)
次要结局
未报告次要终点
研究者
Prof. Franca Fagioli
Principal Investigator
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Clinical study of gemcitabine plus docetaxel in patient with refractory bone and soft tissue sarcomasbone and soft tissue sarcomaJPRN-UMIN000017967Juntendo University Urayasu Hospital10
已完成
2 期
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine CancerRecurrent Uterine Corpus SarcomaUterine CarcinosarcomaNCT00114218Gynecologic Oncology Group28
进行中（未招募）
不适用
Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer. - SF2gem/taxOncologic patients only.MedDRA version: 6.1Level: PTClassification code 10055113EUCTR2006-000165-10-ITA.S.L. 2 SAVONA70
招募中
2 期
Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomasadvanced bone and soft tissue sarcomasJPRN-UMIN000031004Kobe University20
招募中
2 期
GD therapy for advanced sarcomasadvanced pretreated bone and soft tissue sarcomasJPRN-jRCTs051180042Hara Hitomi20